Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical launches Resilience TTS Esophageal Stent to address clinical gaps and expand its endoscopy portfolio with an advanced anti-migration design.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MMSI rides strong cardiovascular demand and fast-growing therapeutic devices, but tariffs, OEM weakness and China macro pressures cloud the outlook.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Merit Medical (MMSI) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MMSI beats Q4 estimates as EPS climbs 12% and margins widen, driven by strong Cardiovascular growth and solid U.S. and EMEA sales.
Merit Medical Systems, Inc. (MMSI) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merit Medical (MMSI) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.93 per share a year ago.
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Merit Medical (MMSI) and Straumann Holding AG (SAUHY). But which of these two companies is the best option for those looking for undervalued stocks?
The mean of analysts' price targets for Merit Medical (MMSI) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.